Janus Henderson Group Ltd. filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 2,344,819 shares of common stock in Korsana Biosciences, Inc., representing 5.2% of the class as of September 30, 2026.

Key Highlights

  • Beneficial ownership: Janus Henderson Group Ltd. reported aggregate beneficial ownership of 2,344,819 shares of Korsana Biosciences common stock.
  • Percent of class: The 2,344,819 shares represent 5.2% of the outstanding class of common stock.
  • Voting and dispositive power: Janus Henderson reported 0 shares with sole voting or sole dispositive power, and 2,344,819 shares with shared voting power and shared dispositive power.
  • Triggering event date: The date of event requiring this filing was September 30, 2026.
  • Filer classification: Janus Henderson Group Ltd. filed as a parent holding company (type HC), organized in Jersey, with its principal business office at 201 Bishopsgate, EC2M 3AE, United Kingdom.
  • Managed Portfolios: According to the filing, none of the individual Managed Portfolios own more than five percent of the common stock of Korsana Biosciences, Inc.

Janus Henderson's Passive Stake in Korsana Biosciences Crosses 5% Threshold

According to the Schedule 13G filed on November 16, 2026, Janus Henderson Group Ltd. (NASDAQ:KRSA is the issuer; the filer is Janus Henderson) disclosed beneficial ownership of 2,344,819 shares of common stock of Korsana Biosciences, Inc. (CUSIP 23255M303), whose principal executive offices are located at 203 Crescent Street, Bldgs 3/3A/4, Suite 503, Waltham, MA 02453. The filing was signed by Kristin Mariani, Head of North America Compliance, on behalf of Janus Henderson Group Ltd.

The filing states that Janus Henderson Group Ltd. is "the ultimate parent of a number of SEC-registered investment advisers and foreign equivalents thereof," including Janus Henderson Investors US LLC, Janus Henderson Investors UK Limited, and several other named Asset Managers. These Asset Managers "generally exercise investment and/or voting discretion on behalf of their clients," referred to collectively as Managed Portfolios, which include investment companies, institutional separate accounts, and retail separate accounts. As a result, the Asset Managers "may be deemed to be the beneficial owner of 2,344,819 common stock of Korsana Biosciences, Inc." The filing further notes that the Asset Managers "do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights."

All 2,344,819 shares are held with shared voting power and shared dispositive power; sole voting power and sole dispositive power are each reported as zero. The filing certifies that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Janus Henderson Group Ltd. filed a Schedule 13G reporting beneficial ownership of 2,344,819 shares, or 5.2%, of Korsana Biosciences, Inc. common stock as of September 30, 2026, held entirely through shared voting and dispositive power across its network of Asset Managers and their Managed Portfolios.